DLL3: competitors of clinically validated target develop effector-enhanced next generation product candidates

STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: DLL3-Targeted Immunotherapy: a Competitor Analysis.

DLL3 is a clinically validated target for treatment of small cell lung cancer which recently started commercialization. Delta-like canonical Notch ligand 3 (DLL3) is minimally expressed in normal tissue but expressed in 80-85% of (small cell lung cancer) SCLC tumors, and approximately 77% of neuroendocrine carcinomas (NECs)1 making DLL3 an ideal therapeutic target for these two indications of high unmet medical need.

Upregulated DLL3 functions as a Notch ligand and has been a target for cancer therapy. DLL3 is fundamental in the downstream cellular signaling for proliferation and apoptosis. DLL3 is an atypical member of the Notch receptor ligand family that is able to inhibit activation of the Notch receptors. DLL3 contains different functional domains (such as a Delta-Serrate-Lag2 [DSL] domain, epidermal growth factor [EGF] repeats, and a transmembrane domain). Aberrant DLL3 expression has been found in neuroendocrine cancers and also high-grade serous ovarian cancer.

SCLC is an aggressive neuroendocrine tumor; response to initial chemotherapy and radiotherapy is often followed by recurrence, rapid progression, and resistance to current therapies. New data show that >75% of castration-resistant small-cell neuroendocrine prostate cancers (CRPC-NE) express the Notch ligand delta-like protein 3 (DLL3). None of the benign and only 0.52% of localized prostate cancer samples were DLL3⁺. By contrast, 12.5% of CRPC adenocarcinomas and 76.6% of CRPC-NE expressed DLL3, and 10.37% and 63.95% of cells in these samples were DLL3⁺, respectively.

The DLL3 target validated by the T-cell engaging antibody tarlatamab-dlle has attracted competitors developing novel anti-DLL3 product candidates with further enhanced effector functions including mono- and bispecific antibody drug, conjugates, radioligand therapies, CAR T- and NK cell therapies, T-cell engaging trispecific antibodies incorporating an immunostimulatory domain and other bispecific antibodies. The field still is in mid-stage clinical development without clear leader in the competition,

This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour. The pdf report includes a compilation of active projects on the market and in research and development of DLL3-targeted products or candidates.

The report “DLL3-Targeted Immunotherapy: a Competitor Analysis” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/dll3-targeted-immunotherapy-a-competitor-analysis/